![]() |
Name |
Hexadecamethylcyclooctasiloxane
|
Molecular Formula | C16H48O8Si8 | |
IUPAC Name* |
2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16-hexadecamethyl-1,3,5,7,9,11,13,15-octaoxa-2,4,6,8,10,12,14,16-octasilacyclohexadecane
|
|
SMILES |
C[Si]1(O[Si](O[Si](O[Si](O[Si](O[Si](O[Si](O[Si](O1)(C)C)(C)C)(C)C)(C)C)(C)C)(C)C)(C)C)C
|
|
InChI |
InChI=1S/C16H48O8Si8/c1-25(2)17-26(3,4)19-28(7,8)21-30(11,12)23-32(15,16)24-31(13,14)22-29(9,10)20-27(5,6)18-25/h1-16H3
|
|
InChIKey |
XKJMJYZFAWYREL-UHFFFAOYSA-N
|
|
Synonyms |
HEXADECAMETHYLCYCLOOCTASILOXANE; 556-68-3; Cyclooctasiloxane, hexadecamethyl-; Hexadecamethyl-cyclooctasioxane; hexadecamethyl-cyclooctasiloxane; 2YAW49T07J; 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16-hexadecamethyl-1,3,5,7,9,11,13,15-octaoxa-2,4,6,8,10,12,14,16-octasilacyclohexadecane; UNII-2YAW49T07J; EINECS 209-137-2; CYCLOMETHICONE 8; Hexadecamethylcycloctasiloxane; SCHEMBL450212; DTXSID0060305; CHEBI:87984; MFCD30725759; AKOS030227996; ZINC195751360; LS-14549; H1288; Q27160001; 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16-Hexadecamethylcyclohexadecaneoctasiloxane; 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16-Hexadecamethylcyclooctasiloxane #; CYCLOOCTASILOXANE, 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16-HEXADECAMETHYL-
|
|
CAS | 556-68-3 | |
PubChem CID | 11170 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 593.2 | ALogp: | 5.7 |
HBD: | 0 | HBA: | 8 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 73.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 32 | QED Weighted: | 0.323 |
Caco-2 Permeability: | -6.222 | MDCK Permeability: | 0.00010523 |
Pgp-inhibitor: | 0.013 | Pgp-substrate: | 0.952 |
Human Intestinal Absorption (HIA): | 0.995 | 20% Bioavailability (F20%): | 0.025 |
30% Bioavailability (F30%): | 0.029 |
Blood-Brain-Barrier Penetration (BBB): | 0 | Plasma Protein Binding (PPB): | 118.05% |
Volume Distribution (VD): | 4.091 | Fu: | 43.52% |
CYP1A2-inhibitor: | 0.169 | CYP1A2-substrate: | 0.969 |
CYP2C19-inhibitor: | 0.866 | CYP2C19-substrate: | 0.968 |
CYP2C9-inhibitor: | 0.882 | CYP2C9-substrate: | 0.982 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.942 |
CYP3A4-inhibitor: | 0.54 | CYP3A4-substrate: | 0.049 |
Clearance (CL): | 2.557 | Half-life (T1/2): | 0.1 |
hERG Blockers: | 0.459 | Human Hepatotoxicity (H-HT): | 0.001 |
Drug-inuced Liver Injury (DILI): | 0.016 | AMES Toxicity: | 0.026 |
Rat Oral Acute Toxicity: | 0 | Maximum Recommended Daily Dose: | 0.335 |
Skin Sensitization: | 0.949 | Carcinogencity: | 0.021 |
Eye Corrosion: | 1 | Eye Irritation: | 0.996 |
Respiratory Toxicity: | 0.022 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000387 | ![]() |
0.889 | D0H2DQ | ![]() |
0.090 | ||
ENC000236 | ![]() |
0.875 | D0Z1ZM | ![]() |
0.085 | ||
ENC001134 | ![]() |
0.800 | D03HJK | ![]() |
0.085 | ||
ENC000372 | ![]() |
0.750 | D06IGU | ![]() |
0.085 | ||
ENC000374 | ![]() |
0.625 | D06ZUP | ![]() |
0.083 | ||
ENC000385 | ![]() |
0.500 | D02YIZ | ![]() |
0.081 | ||
ENC000375 | ![]() |
0.375 | D04JMQ | ![]() |
0.080 | ||
ENC003081 | ![]() |
0.120 | D0TG7I | ![]() |
0.078 | ||
ENC000373 | ![]() |
0.119 | D0E4SI | ![]() |
0.074 | ||
ENC001783 | ![]() |
0.113 | D07VDZ | ![]() |
0.069 |